| Digg It |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Management > How Chief Executives Can Improve Their Performance With Personal Reflection |
|
Digg It - How Chief Executives Can Improve Their Performance With Personal Reflection
Wise experienced leaders from all walks of life tell me that personal reflection is one their most valuable tools for remaining effective and ahead of the game. When I seek to pass this advice on to my clients, I often get thi According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product s question "How does one effectively reflect?" Reflection is the point of maximum learning from one's experiences. Whilst experience is learning, reflection about the experience provides even more learning. To maximise the l ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in earning opportunity from reflection, create a simple process that enables you to think clearly and record your reflections. Here are some tips you can adapt to suit yourself. 1. Choose a regular time to reflect, say 20 minute lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. s early in the morning or at a quiet time in the evening. 2. Choose a quiet place with no disturbances such as phones or TV. 3. Keep a reflection journal to record insights, thoughts or decisions you make. 4. Play soft music here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe - 60 beat per minute works well, or baroque music. 5. Choose a specific experience; event; time block; or relationship for reflection. 6. Ask yourself a series of questions that stimulates deeper and improved insights about d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro the topic of reflection. 7. Here are a series of questions you can build upon or adapt to suit yourself: - a. What are your current dominant impressions about the subject? b. What might lie behind the matter (or betwee ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc n the lines), without making uncheckable assumptions? c. If you were to go through the experience again, what would you do differently? d. Is there another way of looking at this subject? e. Who else could easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi discuss this subject with to get another valuable view? f. What might I be avoiding in connection with this subject? g. What's really important about this subject? h. What action could I best take in conne nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ction with this reflection? Additionally, here are some topics chief executives could reflect upon: - 1. Do you really understand your direct reports – their feelings, concerns, pressures, needs, aims, strengths, weaknesses a and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ nd future? 2. How are you designing the best possible future for your organisation? 3. How are you consistently communicating the values and vision of the organisation to all your people? 4. Do all your people have absolute ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi clarity about their roles tasks and responsibilities in achieving the current goals and vision of the organisation? 5. If there is a noticeable trend for HR professionals to assume the functions that traditionally belong to th ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a e leader, why do you think that might be? 6. Are you unwilling to participate in development/training initiatives together with and at the same as your people, or do you prefer to do that alone or with peers? If so why is th dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod at? 7. Do you have a coach or coaches? 8. Are you more of a leader or more of a high end project manager? 9. If you just discovered your company will run out of funds in five years, what would you do now? 10. Are you willin cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin g to plan now to use alternative fuels and alternative technology? 11. How do you personally attract talent to your organisation and then how do you personally act to retain and develop them? 12. What is your personal ratio o tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen leadership functions to management functions? 13. If the ideal leadership/management ratio is different to the actual, what are you doing about it? 14. Which is more important, effectively engaged employees or delighted shar t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel eholders? 15. To what extent have you become isolated or insulated from your people? 16. Do you have a team of well-chosen people from each area of your business, whose task it is to reduce and streamline the ever growing bur ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust eaucracy? 17. What is the truth about your relationship with your board of directors? 18. Do you know how to make your organisation an employer of choice with a waiting list of talented people? 19. Do you know the relationsh y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products ip between being an employer of choice and your bottom lines? 20. If you died tonight, would your company know who to replace you with? 21. If you discovered you were going to die in a year's time what would become your three . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de top workplace priorities and what would be your three top personal priorities? Reflecting in solitude is really useful. Other times reflecting with a group of trusted people whose values you share, is also very useful. Chie elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip f executives often find themselves isolated. I encourage and support them to form non-competitive and secure self mentoring groups, where they can feel connected and free to discuss issues and help one another grow and improve tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:The Devastation of Over Regulation
|